bioAffinity Technologies Joins National Lung Cancer Roundtable

PUBLISHED ON October 11, 2019

OCTOBER 11, 2019 (San Antonio, TX) bioAffinity Technologies, a privately held biotech company, today announced that it has been accepted as a member of the American Cancer Society’s National Lung Cancer Roundtable (NLCRT), a collaborative whose membership is focused on reducing both the incidence of lung cancer and mortality rates from the disease.

read more

bioAffinity Technologies Announces Members of its Scientific and Medical Advisory Board

PUBLISHED ON October 2, 2019

OCTOBER 2, 2019 (San Antonio, TX) bioAffinity Technologies, a privately held biotech company, today announced the members of its Scientific and Medical Advisory (SMA) Board who will provide independent expert advice and counsel on the Company’s research and development of innovative cancer diagnostics, including CyPath® Lung, a non-invasive test for the early detection of lung cancer.

read more

SA has More Room for Women in Bioscience C-suite

PUBLISHED ON September 6, 2019

San Antonio Business Journal (August 29, 2019) While there is acknowledgment that women have made progress in their climb to executive-level positions in San Antonio's bioscience industry and may find fewer roadblocks here than in some markets, some of the local women leaders in the industry said there is a need to bust a wider hole through the glass ceiling.

read more

Advancing Early Lung Cancer Detection Symposium

PUBLISHED ON May 15, 2019

bioAffinity Technologies proudly will present at Advancing Early Lung Cancer Detection at the Cleveland Clinic, an invitation-only symposium that brings together clinical experts, advocacy groups and industry leaders working to advance new technologies and methods necessary to find lung cancer at its earliest stages.

read more